ADM Antibody (HTA171/E8): sc-53153

ADM Antibody (HTA171/E8) is a mouse monoclonal IgM antibody that detects adrenomedullin (ADM) in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). ADM is a crucial vasodilator produced by various contractile cells, playing a significant role in regulating fluid and electrolyte balance as well as maintaining cardiovascular health. Anti-ADM antibody (HTA171/E8) recognizes ADM in the vascular endothelium and adrenal medulla, where ADM is secreted into the bloodstream to exert systemic effects. This localization enables ADM to act quickly on target tissues, influencing renal function and promoting natriuresis, which is the excretion of sodium in urine. ADM enhances glomerular filtration rate while reducing sodium reabsorption in the distal tubules, underscoring ADM′s importance in fluid homeostasis and blood pressure regulation. ADM has been shown to have central effects, including the modulation of appetite, highlighting ADM′s multifaceted role in both peripheral and central physiological processes. With diverse functions and critical involvement in cardiovascular health, ADM monoclonal antibody (HTA171/E8) serves as an essential tool for researchers studying adrenomedullin′s implications in various physiological and pathological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ADM Antibody (HTA171/E8) References:

1. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP).  |  Wilkinson, IB., et al. 2001. Br J Clin Pharmacol. 52: 159-64. PMID: 11488772
2. Adrenomedullin and diabetes.  |  Wong, HK., et al. 2014. World J Diabetes. 5: 364-71. PMID: 24936257
3. Adrenomedullin and arterial stiffness: integrative approach combining monocyte ADM expression, plasma MR-Pro-ADM, and genome-wide association study.  |  Beygui, F., et al. 2014. Circ Cardiovasc Genet. 7: 634-41. PMID: 25053723
4. Hydroxychloroquine reverses the drug resistance of leukemic K562/ADM cells by inhibiting autophagy.  |  Wang, F., et al. 2019. Mol Med Rep. 20: 3883-3892. PMID: 31485616
5. Do We Need Support in Prepectoral Breast Reconstruction? Comparing Outcomes with and without ADM.  |  Salibian, AA., et al. 2021. Plast Reconstr Surg Glob Open. 9: e3745. PMID: 34386310
6. Matrine reverses the drug resistance of K562/ADM cells to ADM and VCR via promoting autophagy.  |  Li, Z., et al. 2020. Transl Cancer Res. 9: 786-794. PMID: 35117424
7. Pre-Pectoral One-Stage Breast Reconstruction with Anterior Coverage Using Superior Anterior Biological Acellular Dermal Matrix (ADM) and Inferior Anterior Dermal Sling Support.  |  Sisti, A., et al. 2022. Medicina (Kaunas). 58: PMID: 35893107
8. Evaluation of the effect of 3D-bioprinted gingival fibroblast-encapsulated ADM scaffolds on keratinized gingival augmentation.  |  Liu, P., et al. 2023. J Periodontal Res. 58: 564-574. PMID: 37042165
9. Acinar-to-Ductal Metaplasia (ADM): On the Road to Pancreatic Intraepithelial Neoplasia (PanIN) and Pancreatic Cancer.  |  Marstrand-Daucé, L., et al. 2023. Int J Mol Sci. 24: PMID: 37373094
10. Do we need acellular dermal matrix in prepectoral breast reconstruction? A systematic review and meta-analysis.  |  Nolan, IT., et al. 2023. J Plast Reconstr Aesthet Surg. 86: 251-260. PMID: 37793198